Treatment of proliferative diabetic retinopathy with anti-VEGF agents. - Wikidata - wikimedia - TriplyDB

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

http://www.wikidata.org/entity/Q33812021

about

The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction Melatonin-mediated cytoprotection against hyperglycemic injury in Müller cells Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.Biomarkers for Diabetic Retinopathy - Could Endothelin 2 Be Part of the Answer?Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice.Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy.Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy.Novel targets against retinal angiogenesis in diabetic retinopathy.Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Could donor multipotent mesenchymal stromal cells prevent or delay the onset of diabetic retinopathy?Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.Intraocular surgery in a large diabetes patient population: risk factors and surgical results.Heat shock protein-70 and hypoxia inducible factor-1α in type 2 diabetes mellitus patients complicated with retinopathy.Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.Diverse roles of macrophages in intraocular neovascular diseases: a review.Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy.Early retinal pigment epithelium dysfunction is concomitant with hyperglycemia in mouse models of type 1 and type 2 diabetes.Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products.Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy.Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy.Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy.Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.Comparisons of microRNA expression profiles in vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy.Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy.

P2860

Q31061150-F0958C73-2364-4CF1-ABA3-37266A9FC705 Q34313113-2E0CE273-FC58-4980-A42D-1F36C71E645C Q34506566-02A252F5-0C15-4B7F-9C4E-71D30DAABEA8 Q34987495-FC53B343-7EED-4368-88F1-39ED41A49746 Q35055667-A9055A90-5DE7-4B24-831F-6909365B1DD5 Q35078274-75BBCD8F-C194-4CD2-A834-456B16AC2FCD Q35775051-B7B8577D-9BE5-4D6C-A442-1FB20ED8ADC3 Q36092355-66E667A3-7DD4-4853-906A-A4D28923B848 Q36691521-F2A3EFB3-AFA7-45AE-9137-F52593C51345 Q36853911-6A2EB64E-EBFB-4170-AE24-0CF967A98346 Q37251091-FEC18918-B8F7-452B-A2AB-8E2CB529C0CA Q37676783-EC2D5C50-9D7B-49CD-B924-D0D20EAC8351 Q37696872-62B55E4F-3433-415F-86A9-747621F629EB Q38013679-BD90226A-B233-432C-B0A4-D4608FB1A620 Q38030051-07E28DAB-C8E3-481D-95CD-4A42BB2BFCFC Q38115020-34E280D9-8C6B-4914-9274-1EDDEC308BF4 Q41091625-CC907EC4-5A84-4C03-A29A-EFA61FDF1591 Q41970943-DB8ADE4E-67BE-4D29-B607-C76BC4DB1F40 Q44920544-EC4E21E9-0CD4-4031-AD5F-F10ADA174A99 Q46527092-1592DFA4-3AC9-4976-BC82-05B4353A6EAE Q47139871-E6476252-DF56-402A-BDF5-29A0BE70A959 Q47202861-483C8795-D618-4C4E-AACC-497782853D02 Q47446172-49498B87-0325-472C-9494-9FCF45D643C7 Q48169124-2C5EAC4A-078F-471C-873A-2D2C6F4BEC19 Q48300010-0780A2F0-AB55-4FF2-AC33-5530D1ED9E14 Q50066099-2BE67542-E612-4838-8B5E-C4D04D0EEB8C Q50071959-402B4028-520B-4F8A-BC4D-1B4A1AD6D78E Q51069605-52FC1AEC-399D-410D-98CC-AF4B7F0AC79C Q51319850-386EA33C-A121-46B1-B6C3-6CD7D98D9917 Q51720742-D7401DA4-67C3-4336-BD2D-FA73B37CAB5F Q54200577-F891E335-A470-4886-9E84-3B3B26BB21FD Q55097343-9CDD4ECD-BB4C-4DEA-91C6-C6DC8BC7C4F7

P2860

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

http://www.wikidata.org/entity/Q33812021

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@ast

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@en

type

label

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@ast

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@en

prefLabel

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@ast

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@en

P1433

Q33812021-566E80BE-BCC0-445D-97AB-C4FC831135BC

P1476

Q33812021-4E812A08-3C2B-488B-9292-38728D6B9AE8

P2093

Q33812021-322A86FD-5D22-410C-AE46-5DEB8FE133C2

Q33812021-7953CF1B-AFD1-4404-90FC-F1381782A6A5

Q33812021-C9ED48AF-3463-4F7D-86E1-C76B9909AB97

P2860

Q33812021-0549B9D3-01F7-46A6-9099-1CC7DD312B1D

Q33812021-08DE916E-188C-4DE3-BCC3-9A3117AA13F0

Q33812021-0B2E3004-EC42-4899-8C43-F5BE2862ADE1

Q33812021-1E9B7AF1-CD84-4DAA-815E-CD5C726B5315

Q33812021-2398D791-B56E-47B2-A51F-A1218D13BB5B

Q33812021-23A13AED-2194-45C9-B013-09B99CB34E17

Q33812021-25B74F66-13D2-49C2-8661-FCEF4B33934A

Q33812021-2868DF79-4837-42B4-AB28-6EF7CA75D719

Q33812021-2E4B9F1C-EB28-42D0-8508-DAEAA96C5302

Q33812021-32847AE9-FC94-4748-8338-758AF72018D8

P304

Q33812021-29F71462-882E-4E1F-8CF8-F9DA58905540

P31

Q33812021-E1D022A8-F031-42A8-BFA2-50A1427F0094

P356

Q33812021-8E9E1124-C8A7-4DB6-B02B-AF5A28718ECD

P433

Q33812021-C428503C-B0FF-43E6-864B-E07A90C2FCF5

P478

Q33812021-DB59F170-1745-4137-882E-FEA3FC8D0DD7

P577

Q33812021-6563A99F-19A8-4166-8CED-2D3602514775

P5875

Q33812021-0912D1B3-7D46-4C7D-8DF8-8BDC7D2259D9

P698

Q33812021-E5680103-8B2A-468C-8660-5A6ECACC96BD

P356

J.1755-3768.2010.02079.X

P1433

Acta Ophthalmologica

P1476

Treatment of proliferative diabetic retinopathy with anti-VEGF agents.

@en

P2093

Aysha Salam

http://www.w3.org/2001/XMLSchema#string

Raeba Mathew

http://www.w3.org/2001/XMLSchema#string

Sobha Sivaprasad

http://www.w3.org/2001/XMLSchema#string

P2860

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy

Intravitreal bevacizumab for diabetic retinopathy.

Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.

Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy.

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy.

Bevacizumab as adjuvant for neovascular glaucoma.

Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.

P304

405-411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1755-3768.2010.02079.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49811184

http://www.w3.org/2001/XMLSchema#string

P698

21294854

http://www.w3.org/2001/XMLSchema#string